Janus Henderson Global Life Sciences Fund Q4 2024 Commentary
The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...
Wacker Chemie: Strong Market Position Amid Macro Headwinds
Wacker Chemie offers strong growth in semiconductors, solar, and biotech with a 60% upside. Click here to find out why WKCMF ...
Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
Rebranding Invizyne Technologies, Inc to eXoZymes Inc.Changing NASDAQ ticker from IZTC to EXOZIntroducing but not trademarking “exozymes” as a ...
Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...